Literature DB >> 30392150

Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy.

Adnan El-Achkar1, Luis Souhami2, Wassim Kassouf3.   

Abstract

PURPOSE OF THE REVIEW: This review targets the latest literature on bladder preservation therapy with emphasis on trimodal therapy (TMT), highlighting its role in the management of muscle invasive bladder cancer (MIBC) and outlining future directions in bladder preservation research. RECENT
FINDINGS: TMT is the most promising bladder preservation treatment modality. Comparable results to contemporary radical cystectomy series are seen in properly selected patients. A multidisciplinary team approach is critical in the management of these patients. Future research is directed at the integration of immunotherapy into the treatment protocol. TMT, involving maximal transurethral resection followed by chemoradiation, is an attractive alternative to radical cystectomy with urinary diversion in carefully selected patients with muscle invasive disease. In the absence of randomized trial (RCT), comparison between TMT and cystectomy, based on retrospective data from large centers, suggests comparable oncological outcomes, with a favorable impact on quality of life.

Entities:  

Keywords:  Bladder preservation therapy; Chemoradiation; Muscle invasive bladder cancer; Trimodal therapy

Mesh:

Year:  2018        PMID: 30392150     DOI: 10.1007/s11934-018-0859-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  71 in total

1.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Authors:  Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol.

Authors:  Kenji Tanabe; Soichiro Yoshida; Fumitaka Koga; Masaharu Inoue; Shuichiro Kobayashi; Junichiro Ishioka; Tomoki Tamura; Emiko Sugawara; Kazutaka Saito; Takumi Akashi; Yasuhisa Fujii; Kazunori Kihara
Journal:  Clin Genitourin Cancer       Date:  2015-03-27       Impact factor: 2.872

4.  Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.

Authors:  Ross E Krasnow; Michael Drumm; Hannah J Roberts; Andrzej Niemierko; Chin-Lee Wu; Shulin Wu; Jing Zhang; Niall M Heney; Matthew F Wszolek; Michael L Blute; Adam S Feldman; Richard J Lee; Anthony L Zietman; William U Shipley; Jason A Efstathiou
Journal:  Eur Urol       Date:  2016-12-28       Impact factor: 20.096

5.  Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience.

Authors:  Mutahir A Tunio; Altaf Hashmi; Abdul Qayyum; Rehan Mohsin; Ahmed Zaeem
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-09-22       Impact factor: 7.038

6.  Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.

Authors:  M H Hussain; T R Glass; J Forman; W Sakr; D C Smith; M Al-Sarraf; J Jones; S P Balcerzak; E D Crawford; H B Grossman
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

7.  Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.

Authors:  Thomas Seisen; Maxine Sun; Stuart R Lipsitz; Firas Abdollah; Jeffrey J Leow; Mani Menon; Mark A Preston; Lauren C Harshman; Adam S Kibel; Paul L Nguyen; Joaquim Bellmunt; Toni K Choueiri; Quoc-Dien Trinh
Journal:  Eur Urol       Date:  2017-04-12       Impact factor: 20.096

Review 8.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.

Authors:  Sebastien Antoni; Jacques Ferlay; Isabelle Soerjomataram; Ariana Znaor; Ahmedin Jemal; Freddie Bray
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

9.  The hazard of accelerated tumor clonogen repopulation during radiotherapy.

Authors:  H R Withers; J M Taylor; B Maciejewski
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

10.  Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).

Authors:  Robert A Huddart; Emma Hall; Syed A Hussain; Peter Jenkins; Christine Rawlings; Jean Tremlett; Malcolm Crundwell; Fawzi A Adab; Denise Sheehan; Isabel Syndikus; Carey Hendron; Rebecca Lewis; Rachel Waters; Nicholas D James
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-01       Impact factor: 7.038

View more
  5 in total

1.  Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis.

Authors:  Ronald Kool; Ivan Yanev; Tarek Hijal; Marie Vanhuyse; Fabio L Cury; Luis Souhami; Wassim Kassouf; Alice Dragomir
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

Review 2.  Emerging therapeutic agents for genitourinary cancers.

Authors:  Kevin Zarrabi; Azzam Paroya; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2019-09-04       Impact factor: 17.388

Review 3.  Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.

Authors:  Deborah W Knapp; Deepika Dhawan; José A Ramos-Vara; Timothy L Ratliff; Gregory M Cresswell; Sagar Utturkar; Breann C Sommer; Christopher M Fulkerson; Noah M Hahn
Journal:  Front Oncol       Date:  2020-01-21       Impact factor: 6.244

4.  A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer.

Authors:  Zhijie Xu; Hemant Gujar; Guanghou Fu; Hamed Ahmadi; Sumeet Bhanvadia; Daniel J Weisenberger; Baiye Jin; Parkash S Gill; Inderbir Gill; Siamak Daneshmand; Kimberly D Siegmund; Gangning Liang
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

5.  A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.

Authors:  Ben-Max de Ruiter; Maaike W van de Kamp; Jonah P Z van Steenbergen; Martine Franckena; Joost L Boormans; Jeantine M de Feijter; Adriaan D Bins; Maarten C C M Hulshof; Theo M de Reijke; Eva Schaake; Jorg R Oddens
Journal:  Eur Urol Open Sci       Date:  2022-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.